Aurora Private Wealth Inc. Sells 693 Shares of Johnson & Johnson $JNJ

Aurora Private Wealth Inc. lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 19.0% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 2,955 shares of the company’s stock after selling 693 shares during the period. Aurora Private Wealth Inc.’s holdings in Johnson & Johnson were worth $451,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of JNJ. GFG Capital LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at $35,000. Highline Wealth Partners LLC raised its stake in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at $48,000. Finally, von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter worth $49,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $190.66 on Monday. The company has a 50 day moving average of $178.48 and a 200 day moving average of $163.78. The stock has a market cap of $459.16 billion, a P/E ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $192.10. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $24.02 billion during the quarter. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on JNJ shares. Morgan Stanley increased their price objective on shares of Johnson & Johnson from $176.00 to $178.00 and gave the stock an “equal weight” rating in a research report on Friday. The Goldman Sachs Group raised their price target on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday. Wells Fargo & Company set a $212.00 price target on shares of Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. HSBC lifted their price objective on shares of Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. Finally, Citigroup lifted their price objective on shares of Johnson & Johnson from $200.00 to $213.00 and gave the company a “buy” rating in a report on Tuesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $192.94.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.